Yves Levy
Overview
Explore the profile of Yves Levy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
229
Citations
4711
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wiedemann A, Surenaud M, Hubert M, Lopez Zaragoza J, Ribeiro A, Rodrigues C, et al.
J Immunol
. 2025 Mar;
214(2):211-222.
PMID: 40073241
The 2022 Mpox virus (MPXV) outbreak revitalized questions about immunity against MPXV and vaccinia-based vaccines (VAC-V), but studies are limited. We analyzed immunity against MPXV in individuals infected with MPXV...
2.
Lalevee S, Surenaud M, Tariq M, Ingen-Housz-Oro S, Jean-Louis F, Barau C, et al.
J Invest Dermatol
. 2025 Feb;
PMID: 39986436
No abstract available.
3.
Subunit protein CD40.SARS.CoV2 vaccine induces SARS-CoV-2-specific stem cell-like memory CD8 T cells
Nguema L, Picard F, El Hajj M, Dupaty L, Fenwick C, Cardinaud S, et al.
EBioMedicine
. 2024 Dec;
111():105479.
PMID: 39667270
Background: Ideally, vaccination should induce protective long-lived humoral and cellular immunity. Current licensed COVID-19 mRNA vaccines focused on the spike (S) region induce neutralizing antibodies that rapidly wane. Methods: Herein,...
4.
Levy Y, Moog C, Wiedemann A, Launay O, Candotti F, Hardel L, et al.
EClinicalMedicine
. 2024 Dec;
77:102845.
PMID: 39649135
Background: Current HIV prophylactic vaccines evaluate HIV Env as purified proteins. CD40.HIVRI.Env is an innovative antigen delivery targeting gp140 Env from HIV Clade C 96ZM651 to CD40-expressing antigen-presenting cells, thus...
5.
Valayer S, Alexandre M, Prague M, Beavogui A, Doumbia S, Kieh M, et al.
Emerg Microbes Infect
. 2024 Nov;
14(1).
PMID: 39559990
rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo are WHO-prequalified vaccination regimens against Ebola virus disease (EVD). Challenges associated with measuring long-term clinical protection warrant the evaluation of immune response kinetics after vaccination. Data...
6.
Muret K, Le Goff V, Dandine-Roulland C, Hotz C, Jean-Louis F, Boisson B, et al.
Int J Mol Sci
. 2024 Oct;
25(19).
PMID: 39408704
Hidradenitis suppurativa (HS) is a chronic skin disease characterized by painful, recurrent abscesses, nodules, and scarring, primarily in skin folds. The exact causes of HS are multifactorial, involving genetic, hormonal,...
7.
Wiedemann A, Lhomme E, Huchon M, Foucat E, Bererd-Camara M, Guillaumat L, et al.
Nat Commun
. 2024 Sep;
15(1):7666.
PMID: 39227399
Recent Ebola outbreaks underscore the importance of continuous prevention and disease control efforts. Authorized vaccines include Merck's Ervebo (rVSV-ZEBOV) and Johnson & Johnson's two-dose combination (Ad26.ZEBOV/MVA-BN-Filo). Here, in a five-year...
8.
Lacabaratz C, Durand M, Wiedemann A, Foucat E, Surenaud M, Krief C, et al.
J Infect Dis
. 2024 Jul;
231(1):230-240.
PMID: 39012798
Background: The EBL2001 phase 2 trial tested the 2-dose Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine in Europe. Safety and humoral immunogenicity assessments led to European Union market authorization in 2020. Complementary analyses...
9.
Alexandre M, Prague M, Lhomme E, Lelievre J, Wittkop L, Richert L, et al.
Clin Infect Dis
. 2024 May;
79(6):1447-1457.
PMID: 38819800
Background: Analytical treatment interruption (ATI) is the gold standard in HIV research for assessing the capability of new therapeutic strategies to control viremia without antiretroviral treatment (ART). The viral setpoint...
10.
Adriaensen W, Oostvogels S, Levy Y, Leigh B, Kavunga-Membo H, Watson-Jones D
Lancet Infect Dis
. 2024 May;
24(10):e647-e653.
PMID: 38734010
With two endorsed and prophylactic vaccines against Zaire ebolavirus (referred to hereafter as EBOV), the number of individuals vaccinated against EBOV worldwide is estimated to range between 500 000 and...